Idarubicin Hydrochloride
This is the hydrochloride salt form of idarubicin, an anthracycline antibiotic chemotherapy agent used in the treatment of acute myeloid leukemia. It intercalates into DNA and inhibits topoisomerase II to prevent cancer cell division. Cardiac monitoring is essential as cumulative doses can cause cardiomyopathy.
Peso Molecular
534,0000 g/mol
TPSA
177,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl
InChI
InChI=1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10-,15-,16-,17-,21+,26-;/m0./s1
Molecular Formula
C26H28ClNO9
HBD / HBA
6 / 10
Ligações Rotacionáveis
3
Átomos Pesados
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This is the hydrochloride salt form of idarubicin, an anthracycline antibiotic chemotherapy agent used in the treatment of acute myeloid leukemia. It intercalates into DNA and inhibits topoisomerase II to prevent cancer cell division. Cardiac monitoring is essential as cumulative doses can cause cardiomyopathy.
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Yes, Idarubicin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200976. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 636362. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="idarubicin-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/idarubicin-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/idarubicin-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/idarubicin-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="idarubicin-hydrochloride"></drugfyi-drug>